Andrew Cummiskey
ORCID: 0000-0003-0772-4274
· 1 paper in corpus
2025
Background: Avacopan, a selective complement 5a receptor (C5aR) antagonist, is used for the treatment of severe active granulomatosis with polyangiitis (GPA) or microscopic polyangiitis (MPA) in combination with rituximab or cyclophosphami…